//Biosphere tenant Iksuda Therapeutics enters licensing agreement with LegoChem Biosciences

Biosphere tenant Iksuda Therapeutics enters licensing agreement with LegoChem Biosciences

LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program

Iksuda gains worldwide rights to LCBs anti-CD19 ADC LCB73 for development and commercialization in B-cell cancers.

Preclinical data of LCB73 along with clinical outcomes of other CD19-targeted therapies suggest that this ADC represents an effective option for the treatment of various B-cell haematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma – thus matching Iksuda’s goal to develop best-in-class ADCs for hard-to-treat cancers with high unmet need.

Iksuda plans to advance LCB73 into the clinic in a the most efficient manner, utilizing its extensive UK and US based ADC expertise to drive pre-clinical and clinical development activities.

https://iksuda.com/

2020-05-27T11:06:26+00:00